Phase I Study of Escalating Doses of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Trial Profile

Phase I Study of Escalating Doses of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs XL 888 (Primary) ; Vemurafenib
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Jan 2018 Planned End Date changed from 1 Jan 2018 to 1 Feb 2019.
    • 10 Jun 2017 Biomarkers information updated
    • 28 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top